Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Jumpstart Pays Faster than Discovery: The Moral of the TransForm/J&J Acquisition

This article was originally published in Start Up

Executive Summary

With its acquisition of TransForm, J&J has cemented its position as the Big Pharma most interested in the power of jumpstart strategies to create new drugs. The new deal is dwarfed by J&J's 2001 acquisition of Alza, but philosophically the two deals are very much the same--platform technologies that quickly generate relatively low-risk product opportunities for J&J.

You may also be interested in...

European Markets for Erectile Dysfunction Drugs

Three drugs for erectile dysfunction (ED) accounted for sales of $3.1 billion in 2007, according to "European Markets for Erectile Dysfunction Drugs, Devices, and Therapies," a recent report from Medtech Insight. But the European market remained largely underpenetrated in 2007, creating a great business opportunity for some of the smaller specialty pharma and urology-focused device firms focused on ED.

Big Pharma's Biggest Drug Delivery Experiment: Johnson & Johnson

J&J has been Big Pharma's most aggressive experimenter with the drug-delivery and formulations world, but its two biggest transactions haven't provided the value J&J had originally hoped for.

Idun the Latest to Seek Shelter via Pfizer's M&A Highway

In February, Idun Pharmaceuticals became the fourth company acquired by Pfizer in the last 15 months. While those transactions reflect different mixes of product and technology breadth, they suggest a greater alignment between the interests of some private biotechs, their investors, and potential pharma company acquirers, as well as an evolution in the deal calculus for choosing M&A over an alliance or IPO.

Related Content


Related Companies

Related Deals

Latest News



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts